A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis

Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens

(2014) E. Gospodarevskaya et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Evaluation of Initial and Steady-State Gatifloxacin Pharmacokinetics and Dose in Pulmonary Tuberculosis Patients by Using Monte Carlo Simulations

(2013) Wynand Smythe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months? [Short communication]

(2013) P. P. J. Phillips et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project

(2012) Corinne SC Merle et al.   Trials

Global tuberculosis drug development pipeline: the need and the reality

(2010) Zhenkun Ma et al.   LANCET

Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis

(2009) Susan E. Dorman et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

(2009) Marcus B Conde et al.   LANCET

An evaluation of the effects of gatifloxacin on glucose homeostasis

(2008) Ahunna J. Onyenwenyi et al.   PHARMACY WORLD & SCIENCE